Nanobiotix S.A. NBTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.12M | 2.13M | 2.74M | 2.76M | 14.15M |
| Total Other Revenue | 1.11M | 1.12M | 721.70K | 724.90K | 970.40K |
| Total Revenue | 3.23M | 3.25M | 3.47M | 3.48M | 15.12M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3.23M | 3.25M | 3.47M | 3.48M | 15.12M |
| SG&A Expenses | 6.25M | 6.29M | 5.28M | 5.30M | 6.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.65M | 13.73M | 10.27M | 10.32M | 14.65M |
| Operating Income | -10.42M | -10.49M | -6.81M | -6.84M | 462.50K |
| Income Before Tax | -19.93M | -20.05M | -10.82M | -10.86M | -3.05M |
| Income Tax Expenses | 9.30K | 9.40K | -1.70K | -1.80K | 3.40K |
| Earnings from Continuing Operations | -19.94M | -20.06M | -10.81M | -10.86M | -3.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.94M | -20.06M | -10.81M | -10.86M | -3.05M |
| EBIT | -10.42M | -10.49M | -6.81M | -6.84M | 462.50K |
| EBITDA | -10.28M | -10.34M | -6.74M | -6.77M | 916.50K |
| EPS Basic | -0.41 | -0.41 | -0.22 | -0.23 | -0.06 |
| Normalized Basic EPS | -0.25 | -0.25 | -0.13 | -0.13 | -0.05 |
| EPS Diluted | -0.41 | -0.41 | -0.23 | -0.23 | -0.06 |
| Normalized Diluted EPS | -0.25 | -0.25 | -0.13 | -0.13 | -0.05 |
| Average Basic Shares Outstanding | 48.88M | 48.88M | 48.22M | 48.22M | 47.42M |
| Average Diluted Shares Outstanding | 48.88M | 48.88M | 48.22M | 48.22M | 47.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |